GSK's Cabenuva Cut Viral Rebound 7x vs Daily Pills in Adolescent HIV Trial

ViiV Healthcare, GSK’s majority-owned HIV specialist, reported Week 96 results from the LATA Phase 3 trial at the 26th International AIDS Conference in Rio de Janeiro on July 29. Long-acting injectable Cabenuva (cabotegravir + rilpivirine), dosed every two months, was superior to daily oral dolutegravir/tenofovir/lamivudine in 476 virologically suppressed adolescents aged 12 to 19 across Kenya, South Africa, Uganda, and Zimbabwe.

The headline number: confirmed viral rebound occurred in 0.9% (2 of 235) of Cabenuva patients versus 6.4% (15 of 241) on daily oral therapy, a 7x reduction. Patient-reported outcomes backed the clinical result: 94% of adolescents said injections were “much easier” than daily pills.

GSK closed at $53.22 on July 29, giving the company a market cap of roughly $108 billion. Cabenuva is already FDA-approved for adults and adolescents weighing at least 35 kg (initial US approval January 2021; adolescent expansion March 2022), so LATA does not change the label. It strengthens the evidence base for long-acting injectables in the population where adherence is hardest to maintain.

Adolescents in sub-Saharan Africa face the highest treatment-failure risk of any HIV group. Daily pill burden drives the gap between clinical efficacy and real-world outcomes. A bimonthly injection eliminates that burden entirely. The trial was conducted entirely in sub-Saharan Africa, where adolescent retention in care is a recognized public health challenge, and the 7x rebound difference reflects real adherence conditions, not controlled clinical settings.

ViiV stacked two additional datasets alongside LATA. OPERA, a real-world cohort of nearly 6,800 adults, showed Cabenuva maintained high and comparable virologic suppression to daily oral therapy in routine care, with confirmed virologic failure in roughly 1% of patients versus 2% on daily bictegravir/emtricitabine/tenofovir alafenamide. CLARITY follow-up data showed a more favorable injection-site experience with cabotegravir compared to Gilead’s lenacapavir after a single dose.

The pipeline signal is EXTEND 4M, a Phase 2b registrational trial testing a new investigational cabotegravir formulation dosed every four months (three times a year) for HIV prevention. ViiV presented baseline demographics at AIDS 2026. If EXTEND 4M succeeds, GSK’s long-acting franchise extends from treatment into PrEP with even less frequent dosing, competing directly with Gilead’s lenacapavir, which is twice-yearly. The current PrEP field pits ViiV’s Apretude (cabotegravir every two months) against Gilead’s Yeztugo (lenacapavir twice yearly). A four-month cabotegravir formulation would close the dosing-interval gap.

For investors, the competitive picture matters. Gilead and Merck are developing a once-weekly oral ISL/LEN pill that could capture patients who prefer oral dosing, as we examined in our coverage of the ISL/LEN threat. Cabenuva holds the injection-preferring population, but the PrEP market is splitting along dosing-modality lines. EXTEND 4M is the catalyst to watch: Phase 2b data could arrive in 2027, and a four-month injectable would give ViiV a genuine answer to lenacapavir’s twice-yearly advantage.

Risk factors: injection-site reactions remain the primary tolerability concern, and LATA was not powered for rare resistance emergence. The trial was conducted in sub-Saharan Africa, so regulators in the US and EU may require additional data before any label update reflecting superiority claims. EXTEND 4M is early-stage; Phase 2b does not guarantee Phase 3 success.

What It Means for the Trade

GSK’s HIV story has become a two-front war — defending the treatment franchise against Gilead’s lenacapavir while racing toward the next dosing interval — and LATA feeds both fronts. A 7x reduction in viral rebound (0.9% versus 6.4%) in the hardest-to-treat population is the kind of real-world-adjacent evidence that shapes guideline committees and tender procurement across Africa, where most of the global treatment volume sits. Because Cabenuva is already approved in adolescents, LATA is a commercial-ammo readout rather than a label event: the value shows up in country-by-country adoption and ViiV share retention, not in a stock-moving catalyst. The dated catalyst remains EXTEND 4M, with Phase 2b data possible in 2027 — that trial decides whether ViiV has an answer to twice-yearly lenacapavir in PrEP or concedes the dosing-interval war while the Gilead/Merck weekly oral pill attacks from the other side. For a $108 billion company at $53.22, HIV is one of several pillars, but it is the growth pillar investors track most closely.

Mechanism and Market Context

Cabotegravir is an integrase strand-transfer inhibitor and rilpivirine a non-nucleoside reverse-transcriptase inhibitor — an established oral-class pairing reformulated as nanosuspensions for intramuscular injection, giving two-month pharmacokinetics from a single gluteal visit. The entire long-acting thesis is adherence conversion: in HIV, missed doses create both virologic failure and resistance, so translating clinic-trial efficacy into real-world suppression is a logistics problem as much as a pharmacology one. That is why LATA’s design — 476 adolescents across Kenya, South Africa, Uganda, and Zimbabwe, under real adherence conditions — carries weight beyond its size, and why 94% preferring injections over daily pills is a demand signal, not a footnote. The CLARITY injection-site comparison against lenacapavir matters because tolerability at the injection visit is the last remaining friction in the category; OPERA’s roughly 1% failure rate in routine care is the retention proof point payers ask for.

Risks and What Could Go Wrong

1. Gilead’s lenacapavir holds the twice-yearly dosing crown; if EXTEND 4M stumbles, ViiV concedes the interval race for years.
2. The Gilead/Merck once-weekly oral ISL/LEN pill targets the pill-preferring majority — long-acting injectables could end up a large niche rather than the default.
3. LATA was not powered for rare resistance emergence, and integrase resistance to cabotegravir would complicate future sequencing; procurement-driven markets also price aggressively.